Brooks Laboratories Approves Demerger of Manufacturing Business into Abridge Speciality
Brooks Laboratories Ltd · Others (Uncategorized) · 14 Oct 2026, 11:52 pm
Brooks Laboratories Approves Demerger of Manufacturing Business into Abridge Speciality Brooks Laboratories' board approved the demerger of its Manufacturing Business into wholly owned subsidiary Abridge Speciality Limited on a going-concern basis. The demerged unit generated ₹8,287.26 lakhs (96.66% of total turnover) in FY26. Shareholders will receive 1 fully paid equity share of Abridge Speciality for every 1 share held in Brooks Laboratories, maintaining proportional mirror shareholding (52.62% promoter, 47.38% public). Post-scheme, Abridge Speciality will list on BSE and NSE and be renamed Brooks Laboratories Limited, while the residual trading entity will be renamed Xuri Lifesciences Limited. Listing is expected ~16 months from filing.
Original exchange filing (PDF)
More announcements from Brooks Laboratories Ltd
- Intimation of upgrade in Credit Rating · 12 Nov 2026
- Financial Results for the quarter and half year ended September 30, 2026 · 07 Nov 2026
- Financial Results for the quarter and half year ended September 30, 2026 · 07 Nov 2026
- Brooks Laboratories Limited has submitted to the Exchange, the financial results for the quarter and half year ended September 30, 2026. · 07 Nov 2026
- Financial Results for the quarter and half year ended September 30, 2026 · 07 Nov 2026
- To consider and approve the financial results for the period ended September 30, 2026 · 07 Nov 2026
- Brooks Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2026 ,inter alia, to consider and approve the Unaudited Standalone .... · 07 Nov 2026
- Brooks Laboratories Limited has informed the BSE that the meeting of Board of Directors of the Company is scheduled on 07/11/2026, inter alia, to consider and approve take on records the .... · 03 Nov 2026
